The question
Does failed insulin signalling in brain cells start Alzheimer's disease?
This is the specific idea being tested.
The Hypothesis Critic · A guide for everyone
Metabolic / 'Type 3 Diabetes' Hypothesis
Does failed insulin signalling in brain cells start Alzheimer's disease?
What you need to knowInsulin-related problems may worsen disease, but are not established as its primary starting cause.Relative explanatory fit: Alternative ranked ahead
Why the alternative fits better: Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route.
Review summary
Claim assessed: Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.
Finding: Γ follows the preregistered weakest-link bundle (Γ,Ε,Γ,Γ); primary-SC3 and scope-matched sensitivities also return Γ. Model-specific causal contribution earns Ε, while primary sporadic neuronal initiation and clinically proven correction remain unestablished. Functional tissue resistance, acute memory effects, peripheral prevention and FDG changes are kept distinct. Positive models and valid human causal equivalents are assessed together, without automatically re-capping their weaker observational members.
Key points
- SC1: Brain insulin resistance is present independently of peripheral type2 diabetes. — HSEF Γ, Moderate confidence.
- SC2: Failure of neuronal insulin signaling contributes causally to AD pathology. — HSEF Ε, Moderate confidence.
- SC3: Neuronal insulin resistance is upstream of amyloid and tau. — HSEF Γ, Moderate confidence.
- SC4: Insulin-targeting therapy modifies clinical disease trajectory. — HSEF Γ, Moderate confidence.
Verdict and review details
- Evidence grade
- HSEF Γ — Mechanistically plausible, partial system support
- Confidence
- Moderate
- Framework
- HSEF v5.3
- Review date
- Literature cutoff
- Published
- Review attribution (recorded)
- Codex
Evidence scope: 68 primary reports; literature cutoff 2026-10-05; source examination UTC date 2026-10-06; bounded critical review, not exhaustive systematic review.
The grade applies to the stated claim. Model rankings and individual subclaim grades remain separate from the overall causal-evidence grade.
Full scientific assessment and references · Scorecard (JSON) · Review source (Markdown)
The result at a glance
Insulin-related problems may worsen disease, but are not established as its primary starting cause.
Read the labels in this illustration
THE MAIN FINDING Insulin-related problems may worsen disease, but are not established as its primary starting cause. The idea Does failed insulin signalling in brain cells start Alzheimer's disease? Failed insulin signalling Alzheimer's disease begins Proposed chain — plausible, not established What fits better Brain injury and insulin problems feed back Best fit in this review Injured neuron with insulin receptors Disrupted signalling, inflammation, low energy feed back Tau in nerve cells Insulin receptors Cell energy Inflammation What remains uncertain Whether insulin problems start disease in anyone Which signalling branch matters most How much insulin problems add to dysfunction Evidence comes from cells, animals, and people — each setting carries different weight. Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route. Conceptual illustration
Best fit in this review
Brain injury and insulin problems feed back
Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route.
Evidence for the stated claim
Plausible, not established
A higher rank means a better fit to the evidence in this comparison. It does not prove every part of the leading explanation.
Which explanation fits?
Another explanation fits better.
A separate question from the causal evidence grade
How does this explanation compare with alternatives?
Alternative ranked aheadThe reviewed hypothesis ranks 5 among 5 models compared; 1 alternative model(s) hold first rank for this stated claim.
Claim under review: rank 5 among 5 compared models.
Leading explanation: Amyloid/tau-induced resistance with feedback.
Position in this comparison: Last recorded rank.
The causal grade asks how well the stated causal claim is established. This comparison asks which of the assessed explanations fits the reviewed findings better. A leading explanation can remain unproven. Models can overlap or include the tested mechanism; an alternative ahead does not make that mechanism irrelevant. These ordinal ranks apply within this review; they do not measure the size of a difference or rank scientific strength across topics.
Read the labels in this illustration
WHY THE COMPARISON MATTERS A · The idea under review Does failed insulin signalling in brain cells start Alzheimer's disease? B · Leading explanation Brain injury and insulin problems feed back Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route. Another explanation fits better A better fit is not proof of every part of the explanation. Compatible mechanisms may overlap. Conceptual illustration Insulin signalling fails Alzheimer's disease starts (proposed consequence) Proposed sequence — not established Brain injury Insulin signalling problems feed back
Idea being tested · rank 5
Does failed insulin signalling in brain cells start Alzheimer's disease?
Plausible, not established for the stated claim.
Best fit in this review · rank 1
Brain injury and insulin problems feed back
Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route.
These explanations can overlap. Ranking their fit to the evidence is separate from deciding how firmly a cause has been established.
See all the explanations compared
Rank 1: Amyloid/tau-induced resistance with feedback — AD-related injury can disrupt insulin-related signalling, which can amplify subsequent dysfunction.
Rank 2: Permissive neurotrophic support — Insulin-related signalling supports synapses and memory without constituting a primary AD trigger.
Rank 3: Neurovascular/peripheral metabolic contribution — Metabolic risk can act through systemic and vascular routes without primary neuronal receptor failure.
Rank 4: Reduced synaptic demand and secondary glucose change — Loss of synapses/cells or altered transport can produce FDG and tissue-glucose abnormalities.
Rank 5: Primary neuronal insulin/IGF failure — A native neuronal signalling defect precedes and drives sporadic AD, and correcting it modifies clinical trajectory.
What this means
?
Plausible, not established
Insulin-related problems may worsen disease, but are not established as its primary starting cause.
Evidence rating: Γ · Moderate confidence. How the evidence was assessed.
The important distinction
Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route.
Health and treatment
This is an assessment of a causal explanation, not proof that a particular supplement, diet, test, or treatment improves health. A treatment claim needs studies that test the intervention in people and measure meaningful benefits and harms. These findings can help frame research and informed clinical questions, but they do not identify what is right for one person.
From an idea to an explanation
Seeing two things together does not prove one causes the other.
What is observed?
Look for the proposed factor and the outcome, in the people or systems covered by the claim.
What else explains it?
Brain injury and insulin problems feed back. Alzheimer's-related injury disrupts insulin signalling, which may add to dysfunction. This fits better than one insulin-first route.
What test tells them apart?
Correct signalling selectively, testing prevention of early amyloid, tau and functional changes.
Key questions
The key parts of the idea
These illustrations show the key questions tested in the review. They are conceptual drawings, not microscope images or experimental results.
What to test next
What evidence would make the answer clearer?
Read the labels in this illustration
A research question Correct signalling selectively, testing prevention of early amyloid, tau and functional changes. 1 · Change the proposed cause Proposed test Control Correct insulin signalling selectively No signalling correction 2 · Measure the relevant outcome Proposed test Control Measure early amyloid, tau and functional changes Same measures in control 3 · Check the result independently Proposed test Control An independent team repeats the same setup Compare test and control Conceptual illustration
A useful next question
Correct signalling selectively, testing prevention of early amyloid, tau and functional changes.
Change the proposed cause
Check that the intended change really happened.
Measure the relevant outcome
Allow for other factors and compare with suitable controls.
Check whether it holds up
Look for independent confirmation and the limits of the effect.
These are questions for research, not a claim that the proposed studies have already succeeded.
Read the scientific study designs
Proposed tests: 1 test design(s) are registered in the scorecard.
In plain terms, researchers would change the proposed cause, check that it changed as intended, then measure a meaningful outcome while controlling plausible alternatives. The result should be able to support or count against the claim—not only show that a pathway exists.
Experiment 1: Registered boundary experiment
Study design: Predefine an amyloid/tau-negative sporadic-risk cohort with validated live neuron-specific insulin-response measurements; triangulate a selective neuronal exposure instrument and an early CNS-delivered intervention that corrects that response, with matched adult conditional model loss/rescue and repeated pathology/function follow-up.
What would be measured: Incident biomarker-confirmed AD and durable cognitive/daily-function trajectory with temporal neuronal mediator correction
Important controls: Peripheral glycemia, vascular perfusion, intake/weight, IGF branch, glial engagement, validated delivery device, inactive exposure and prespecified multiplicity
Result that would support the claim: Resistance precedes lesions and selective correction prevents conversion through measured neuronal mediation, independently replicated
Result that would count against it: Resistance follows lesions or selective correction changes signalling without pathology/functional benefit, while systemic/vascular effects explain treatment associations
Explore the evidence
Read the complete scientific review.
Follow the studies, detailed comparisons and evidence ratings behind this guide.
Open the scientific review →